Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 985 results.
User Information
Export Records
  1. 1.   Distinct allosteric networks in CDK4 and CDK6 in the cell cycle and in drug resistance
  2. Zhang,Wengang; Bradburn, Devin; Heidebrink, Gretchen; Liu, Yonglan; Jang,Hyunbum; Nussinov,Ruth; Kõivomägi, Mardo
  3. Journal of Molecular Biology. 2025, Mar 31; 169121.
  1. 2.   Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
  2. Cecchini, Michael; Pilat, Mary Jo; Uboha, Nataliya; Azad, Nilofer S; Cho, May; Davis, Elizabeth J; Ahnert, Jordi Rodon; Tinoco, Gabriel; Shapiro, Geoffrey I; Khagi, Simon; Powers, Benjamin; Spencer, Kristen; Groisberg, Roman; Drappatz, Jan; Chen, Li; Das,Bishu; Bao, Xun; Li, Jing; Narayan, Azeet; Vu, Dennis; Patel, Abhijit; Niger, Monica; Doroshow, Deborah; Durecki, Diane; Boerner, Scott A; Bindra, Ranjit; Ivy, Percy; Shyr, Derek; Shyr, Yu; LoRusso, Patricia M
  3. Cancer. 2025, Feb 15; 131(4): e35755.
  1. 3.   Drug-Linker Constructs Bearing Unique Dual-Mechanism Tubulin Binding Payloads Tethered through Cleavable and Non-Cleavable Linkers
  2. Ford, Jacob W; VanNatta, Jennifer M; Mondal, Deboprosad; Lin, Chen-Ming; Deng, Yuling; Bai, Ruoli; Hamel,Ernest; Trawick, Mary Lynn; Pinney, Kevin G
  3. Tetrahedron. 2025, Feb 01; 171
  1. 4.   Fine-tuning probes for fluorescence polarization binding assays of bivalent ligands against polo-like kinase 1 using full-length protein
  2. Tsuji, Kohei; Tamamura, Hirokazu; Burke,Terrence
  3. Bioorganic & Medicinal Chemistry . 2024, Dec 28; 119: 118055.
  1. 5.   The differential interactomes of the KRAS splice variants identify BIRC6 as a ubiquitin ligase for KRAS4A
  2. Kochen Rossi, Juan; Nuevo-Tapioles, Cristina; O'Keefe, Rachel A; Hunkeler, Moritz; Schmoker, Anna M; Fissore-O'Leary, Mercedes; Su, Wenjuan; Ahearn, Ian M; Branco, Cristina; Cheong, Hakyung; Esposito,Dom; Clotea, Ioana; Ueberheide, Beatrix; Fischer, Eric S; Philips, Mark R
  3. Cell Reports. 2024, Dec 19; 44(1): 115087.
  1. 6.   A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS): Adolescent and adult subgroup analysis
  2. Rao, V Koneti; Šedivá, Anna; Dalm, Virgil A S H; Plebani, Alessandro; Schuetz, Catharina; Shcherbina, Anna; Trizzino, Antonino; Zharankova, Yulia; Orpia, Alanvin; Kulm,Elaine; Webster, Sharon; Körholz, Julia; Lougaris, Vassilios; Rodina, Yulia; Conlon, Niall; Coulter, Tanya; Bradt, Jason; Relan, Anurag; Uzel, Gulbu
  3. Clinical Immunology (Orlando, Fla.). 2024, Nov 17; 110400.
  1. 7.   Design, Synthesis and Biological Evaluation of 2-Phenyl Indole Analogues of OXi8006 as Colchicine Site Inhibitors of Tubulin Polymerization and Vascular Disrupting Agents
  2. Vairin, Rebecca; Tamminga, Caleb; Shi, Zhe; Borchardt, Christian; Jambulapati, Jayaram; Bai, Ruoli; Wanniarachchi, Hashini; Bueno, Lorena; Hamel,Ernest; Mason, Ralph P; Trawick, Mary Lynn; Pinney, Kevin G
  3. Bioorganic & Medicinal Chemistry. 2024, Nov 07; 118: 117981.
  1. 8.   Bisubstrate inhibitors of 6-hydroxymethyl-7,8-dihydroptein pyrophosphokinase: Toward cell permeability
  2. Shi,Genbin; Shaw,Gary; Ji,Xinhua
  3. Bioorganic & Medicinal Chemistry Letters. 2024, Sep 25; 129977.
  1. 9.   MoMo30 Binds to SARS-CoV-2 Spike Variants and Blocks Infection by SARS-CoV-2 Pseudovirus
  2. DeBarros, Kenya; Khan, Mahfuz; Coleman, Morgan; Bond, Vincent C; Floyd, Virginia; Gbodossou, Erick; Diop, Amad; Krumpe,Lauren; O'Keefe,Barry; Powell, Michael D
  3. Viruses. 2024, Sep 07; 16(9):
  1. 10.   Novel Arf1 Inhibitors Drive Cancer Stem Cell Aging and Potentiate Anti-Tumor Immunity
  2. Wang, Yuetong; Li, Qiaoming; Ding, Yahui; Luo, Chenfei; Yang, Jun; Wang, Na; Jiang, Ning; Yao, Tiange; Wang, Guohao; Shi, Guoming; Hou, Steven X
  3. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 2024, Sep 03; e2404442.
  1. 11.   Guanylate-binding protein 5 antagonizes viral glycoproteins independently of furin processing
  2. Veler,Hana; Lun, Cheng Man; Waheed,Abdul; Freed,Eric
  3. mBio. 2024, Aug 30; e0208624.
  1. 12.   The SRC family kinase inhibitor NXP900 demonstrates potent anti-tumor activity in squamous cell carcinomas
  2. Dash,Sweta; Hanson, Sabrina; King, Ben; Nyswaner, Katherine; Foss, Kelcie; Tesi,Noelle; Harvey, Mungo J B; Navarro-Marchal, Saúl A; Woods, Allison; Poradosu, Enrique; Unciti-Broceta, Asier; Carragher, Neil O; Brognard,John
  3. The Journal of Biological Chemistry. 2024, Jul 30; 107615.
  1. 13.   Synthesis and Biological Evaluation of Novel 2-Aroyl Benzofuran-Based Hydroxamic Acids as Antimicrotubule Agents
  2. Mariotto, Elena; Canton, Martina; Marchioro, Chiara; Brancale, Andrea; Hamel,Ernest; Varani, Katia; Vincenzi, Fabrizio; De Ventura, Tiziano; Padroni, Chiara; Viola, Giampietro; Romagnoli, Romeo
  3. International Journal of Molecular Sciences. 2024, Jul 09; 25(14):
  1. 14.   Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization
  2. Becker, William; Olkhanud, Purevdorj B; Seishima, Noriko; Moreno, Paloma A; Goldfarbmuren,Kate; Maeng, Hoyoung M; Berzofsky, Jay A
  3. Journal for Immunotherapy of Cancer. 2024, Jul 01; 12(7):
  1. 15.   Slower CDK4 and faster CDK2 activation in the cell cycle
  2. Zhang,Wengang; Liu,Yonglan; Jang,Hyunbum; Nussinov,Ruth
  3. Structure (London, England : 1993). 2024, Apr 23;
  1. 16.   Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer
  2. Furusawa, Takashi; Cavero, Renzo; Liu, Yue; Li, Haojian; Xu,Xia; Andresson,Thorkell; Reinhold, William; White, Olivia; Boufraqech, Myriem; Meyer,Thomas; Hartmann, Oliver; Diefenbacher, Markus E; Pommier, Yves; Weyemi, Urbain
  3. Molecular Carcinogenesis. 2024, Feb 27;
  1. 17.   Inhibition of Plasmodium falciparum plasmepsins by drugs targeting HIV-1 protease: A way forward for antimalarial drug discovery
  2. Mishra, Vandana; Deshmukh, Anuradha; Rathore, Ishan; Chakraborty, Satadru; Patankar, Swati; Gustchina,Alla; Wlodawer,Alexander; Yada, Rickey Y; Bhaumik, Prasenjit
  3. Current Research in Structural Biology. 2024, Jan 17; 7: 100128.
  1. 18.   Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR
  2. Sharma,Alok; Pei, Jun; Yang, Yue; Dyba,Marcin; Smith,Brian; Rabara,Dana; Larsen,Erik; Lightstone, Felice C; Esposito,Dom; Stephen,Andy; Wang, Bin; Beltran, Pedro J; Wallace, Eli; Nissley,Dwight; McCormick, Frank; Maciag,Anna
  3. The Journal of Biological Chemistry. 2024, Jan 16; 300(2): 105650.
  1. 19.   SHP2 clinical phenotype, cancer, or RASopathies, can be predicted by mutant conformational propensities
  2. Liu,Yonglan; Zhang,Wengang; Jang,Hyunbum; Nussinov,Ruth
  3. Cellular and Molecular Life Sciences : CMLS. 2023, Dec 12; 81(1): 5.
  1. 20.   SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer
  2. Ohara, Yuuki; Tang, Wei; Liu, Huaitian; Yang, Shouhui; Dorsey, Tiffany H; Cawley, Helen; Moreno, Paloma; Chari,Raj; Guest,Mary; Azizian, Azadeh; Gaedcke, Jochen; Ghadimi, Michael; Hanna, Nader; Ambs, Stefan; Hussain, S Perwez
  3. Cell Reports. 2023, Nov 18; 42(12): 113434.
  1. 21.   Interim Analysis: Open-Label Extension Study of Leniolisib for Patients with APDS
  2. Rao, V Koneti; Kulm,Elaine; Šedivá, Anna; Plebani, Alessandro; Schuetz, Catharina; Shcherbina, Anna; Dalm, Virgil A; Trizzino, Antonino; Zharankova, Yulia; Webster, Sharon; Orpia, Alanvin; Körholz, Julia; Lougaris, Vassilios; Rodina, Yulia; Radford, Kath; Bradt, Jason; Relan, Anurag; Holland, Steven M; Lenardo, Michael J; Uzel, Gulbu
  3. The Journal of Allergy and clinical immunology.. 2023, Oct 03;
  1. 22.   First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Ra, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
  2. Leidner, Rom; Conlon, Kevin; McNeel, Douglas G; Wang-Gillam, Andrea; Gupta, Sumati; Wesolowski, Robert; Chaudhari, Monica; Hassounah, Nadia; Lee, Jong Bong; Ho Lee, Lang; O'Keeffe, Jessica A; Lewis, Nancy; Pavlakis,George; Thompson, John A
  3. Journal for Immunotherapy of Cancer. 2023, Oct; 11(10):
  1. 23.   Dihydroxyphenyl- and Heteroaromatic-Based Thienopyrimidinones to Tackle HIV-1 LEDGF/p75-Dependent IN Activity
  2. Tocco, Graziella; Canton, Serena; Laus, Antonio; Caboni, Pierluigi; Le Grice, Stuart F J; Tramontano, Enzo; Esposito, Francesca
  3. Molecules (Basel, Switzerland). 2023, Sep 19; 28(18):
  1. 24.   Synthesis and biological evaluation of structurally diverse 6-aryl-3-aroyl-indole analogues as inhibitors of tubulin polymerization
  2. Ren, Wen; Deng, Yuling; Ward, Jacob D; Vairin, Rebecca; Bai,Ruoli; Wanniarachchi, Hashini I; Hamal, Khagendra B; Tankoano, Pouguiniseli E; Tamminga, Caleb S; Bueno, Lorena M A; Hamel,Ernest; Mason, Ralph P; Trawick, Mary Lynn; Pinney, Kevin G
  3. European Journal of Medicinal Chemistry. 2023, Sep 06; 263: 115794.
  1. 25.   Specific inhibition of an anticancer target, polo-like kinase 1, by allosterically dismantling its mechanism of substrate recognition
  2. Park, Jung-Eun; Kirsch, Klara; Lee, Hobin; Oliva, Paola; Ahn, Jong Il; Ravishankar, Harsha; Zeng, Yan; Fox,Stephen; Kirby, Samuel A; Badhwar, Pooja; Andresson,Thorkell; Jacobson, Kenneth A; Lee, Kyung S
  3. Proceedings of the National Academy of Sciences of the United States of America. 2023, Aug 29; 120(35): e2305037120.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel